195 related articles for article (PubMed ID: 25335860)
1. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
2. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
3. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
4. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
Boyce M; Warrington S
Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
[TBL] [Abstract][Full Text] [Related]
6. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
7. Randomized Controlled Trial of the Gastrin/CCK
Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
[TBL] [Abstract][Full Text] [Related]
8. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
9. CCK2 receptor antagonists: pharmacological tools to study the gastrin-ECL cell-parietal cell axis.
Håkanson R; Ding XQ; Norlén P; Lindström E
Regul Pept; 1999 Mar; 80(1-2):1-12. PubMed ID: 10235629
[TBL] [Abstract][Full Text] [Related]
10. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical indications for a CCK
Boyce M; Lloyd KA; Pritchard DM
Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
[TBL] [Abstract][Full Text] [Related]
12. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
[TBL] [Abstract][Full Text] [Related]
13. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
14. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
15. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.
Barrett TD; Lagaud G; Wagaman P; Freedman JM; Yan W; Andries L; Rizzolio MC; Morton MF; Shankley NP
Br J Pharmacol; 2012 Jul; 166(5):1684-93. PubMed ID: 22300007
[TBL] [Abstract][Full Text] [Related]
16. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
[TBL] [Abstract][Full Text] [Related]
17. Time-course of deactivation of rat stomach ECL cells following cholecystokinin B/gastrin receptor blockade.
Ding XQ; Lindström E; Håkanson R
Br J Pharmacol; 1997 Sep; 122(1):1-6. PubMed ID: 9298521
[TBL] [Abstract][Full Text] [Related]
18. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022.
Kitano M; Norlén P; Ding XQ; Nakamura S; Håkanson R
Br J Pharmacol; 2000 Jun; 130(3):699-705. PubMed ID: 10821801
[TBL] [Abstract][Full Text] [Related]
19. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
[TBL] [Abstract][Full Text] [Related]
20. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development.
Kidd M; Siddique ZL; Drozdov I; Gustafsson BI; Camp RL; Black JW; Boyce M; Modlin IM
Regul Pept; 2010 Jun; 162(1-3):52-60. PubMed ID: 20144901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
